The June edition of the Journal of Thoracic Oncology features a study aimed at determining the optimal dose of the chemotherapy drug nab- paclitaxel with carboplatin as a first-line therapy in patients with non-small cell lung cancer (NSCLC). Results will provide researchers . Source: General Cancer News Articles Provided by Cancer [...]
Local patients with so-called non-smokers’ lung cancer are being recruited to take part in a Yale University study that could determine whether an experimental Pfizer Inc. medicine wins regulatory approval. Source: General Cancer News Articles Provided by Cancer Compass
Targeted therapy based on molecular signatures for treating lung cancer The first lung cancer clinical trial to guide targeted therapies to patients based on molecular signatures in tumor biopsies is a step toward personalized care and more effective, efficient clinical trials for new drugs, study leaders reported today during the American Association for Cancer Research 101st [...]
An experimental drug is showing promise for the treatment of men with an aggressive form of advanced prostate cancer. A new multicenter study has concluded that the targeted therapy MDV3100 is safe and effective for patients with castration-resistant prostate cancer (CRPC), known for its poor prognosis and limited [...]
In 1950, Dr. Haskell applied negative ions to patients of hypertension. Amazingly, negative ions were proven to have a significant effect in lowering one’s blood pressure, while no beneficial effects were observed with positive ions. Negative Ion are also effective against influenza, asthma and especially bronchial diseases.
Another study done by the University of Frankfurt involved [...]
Oncologists at Maimonides Cancer Center, a melting-pot hospital in Brooklyn, NY, discuss the challenges they face treating patients whose culture makes talking about their disease taboo. wsj’s Lucette Lagnado reports. (Oct. 4)
In a new approach to developing treatments for breast cancer, prostate cancer and enlarged hearts, Loyola University Chicago Stritch School of Medicine researchers are zeroing in on a workhorse protein called RSK. Source: General Cancer News Articles Provided by Cancer Compass
Researchers have discovered genetic mutations that may contribute to the development of an aggressive form of non-Hodgkin’s lymphoma. These findings provide insight into a mechanism that cancer cells may use to survive, thus identifying potential new targets for treatment of the disease. Source: NCI News Releases